Mechanistic Insights into AKT1/GSK3β/CD36 Axis Regulation in ZLY06-Induced Hepatic Lipid Metabolism Dysfunction and Protective Intervention via AKT Activation Strategies
{{output}}
The safety of compounds, particularly hepatotoxicity, is a critical focus in drug development. The novel PPARβ/γ dual agonist ZLY06, a candidate compound for the treatment of metabolic syndrome, exhibited significant hepatotoxic effects in animal studies, ch... ...
